• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NanoVibronix Inc.

    6/25/25 4:05:18 PM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.    )

     

    Filed by the Registrant  ☒
    Filed by a Party other than the Registrant  ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the SEC Only (As Permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    NanoVibronix, Inc.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

    SUPPLEMENT TO DEFINITIVE PROXY STATEMENT

    FOR THE SPECIAL MEETING OF STOCKHOLDERS

    TO BE HELD ON JULY 11, 2025

     

    EXPLANATORY NOTE

     

    On June 20, 2025, NanoVibronix, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement on Schedule 14A (the “Proxy Statement”) relating to the Company’s Special Meeting of Stockholders (the “Special Meeting”) to be held on Friday, July 11, 2025, commencing at 10:00 a.m., Eastern Time. As previously disclosed, the board of directors of the Company has fixed the close of business on May 16, 2025, as the record date (the “Record Date”) for determining stockholders entitled to vote at the Special Meeting and at any adjournment(s) or postponement(s) thereof. Capitalized terms used in this supplement to the Proxy Statement (this “Supplement”) without definition have the same meanings as set forth in the Proxy Statement.

     

    This Supplement is being filed to correct an inadvertent error in the number of shares of preferred stock reported as outstanding as of the Record Date on page 3 of the Proxy Statement. On page 3 thereof, the Proxy Statement previously stated that there were no shares of any series of preferred stock outstanding, when there were 320,348 shares of Series G Preferred Stock and 57,720 shares of Series X Preferred Stock of the Company issued and outstanding as of the Record Date. This change solely affects the disclosure as related to such shares of preferred stock outstanding as of the Record Date as reported on page 3 of the Proxy Statement.

      

    This Supplement should be read in conjunction with the Proxy Statement. Except as specifically amended or supplemented by the information contained herein, this Supplement does not otherwise modify, amend or supplement the Proxy Statement, and the information contained in the Proxy Statement should be considered in voting your shares. From and after the date of this Supplement, any references to the “Proxy Statement” are to the Proxy Statement as supplemented hereby.

     

    If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote.

     

    ***

     

    The following text replaces, in its entirety, the text on page 3 of the Proxy Statement appearing below “Who is entitled to vote at the Special Meeting and how many votes do they have?”

     

    Holders of Common Stock at the close of business on the Record Date, may vote at the Special Meeting. There were 2,282,746 shares of Common Stock, 0 shares of Series C Preferred Stock, 0 shares of Series D Preferred Stock, 0 shares of Series E Preferred Stock, 0 shares of Series F Preferred Stock, 320,348 shares of Series G Preferred Stock and 57,720 shares of Series X Preferred Stock issued and outstanding on the Record Date. A complete list of registered stockholders entitled to vote at the Special Meeting will be available for inspection at the principal executive offices of the Company during regular business hours for the 10 calendar days prior to the Special Meeting.

     

    Pursuant to the rights of our stockholders contained in our charter documents, each share of our Common Stock is entitled to one vote on all matters listed in this proxy statement. There is no cumulative voting. 

     

     

     

    Get the next $NAOV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    SEC Filings

    See more
    • SEC Form DEFA14A filed by NanoVibronix Inc.

      DEFA14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/25/25 4:05:18 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by NanoVibronix Inc.

      DEF 14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/20/25 8:00:09 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by NanoVibronix Inc.

      PRE 14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/9/25 5:13:23 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Murphy Brian M

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/3/25 4:05:16 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Mika Thomas

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:26:30 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:25:07 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoVibronix Announces CEO Transition

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

      6/4/25 8:38:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

      12/15/22 4:05:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Reports First Quarter 2022 Financial Results

      Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

      5/17/22 8:30:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

      Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division ("ENvue" or "ENvue Medical"). The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement of nasoenteric feeding tubes in adult patients. ENvue's electromagnetic technology provides clinicians with real-time visualization of tube directi

      6/24/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

      Patent strengthens ENvue's IP position as it advances toward pediatric regulatory clearance and expanded clinical use NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical" or "ENvue"), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled "Insertion Device Positioning Guidance System," further strengthens ENvue Medical's intellectual property portfolio and reflects the Company's ongoing commitment to innovation in feeding tube placement technologies. This newly granted patent cover

      6/11/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces CEO Transition

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

      6/4/25 8:38:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Financials

    Live finance-specific insights

    See more
    • NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

      NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

      9/14/22 9:25:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      11/14/24 5:17:34 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by NanoVibronix Inc.

      SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

      2/14/24 3:45:41 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      2/16/21 3:49:24 PM ET
      $NAOV
      Industrial Specialties
      Health Care